News
Low-dose aspirin reduces liver fat, inflammation markers
- Author:
- Neil Osterweil
“I’m encouraged by the results with low-dose aspirin, and I think that, given the risk profile, using a lower dose is preferable.”
News
Weight-loss drugs improve liver measures, too
- Author:
- Neil Osterweil
Body weight reduction of at least 3% within 8 weeks of beginning treatment with either an SLT-2 or GLP-1 agent was associated independently with...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Le_Phuc_OH_web.jpg)
MASLD, MASH projected to grow by 23% in the U.S. through 2050
- Author:
- Neil Osterweil
“In the absence of effective treatments, health systems should plan for large increases in the number of liver cancer cases and the need for liver...
News
ACORN: No excess AKI with pip-tazo vs. cefepime
- Author:
- Neil Osterweil
Results of the randomized trial suggest that clinicians can safely prescribe empiric piperacillin-tazobactam for serious acute infections.
News
Race-specific lung-function values may skew IPF testing
- Author:
- Neil Osterweil
Race-specific equations may falsely inflate percent-predicted pulmonary function values in non-White patients, investigators caution.
News
Dato-DXd trumps chemo in advanced HR+/HER2– breast cancer
- Author:
- Neil Osterweil
The antibody-drug conjugate datopotamab deruxtecan had better efficacy and safety than chemotherapy for patients with endocrine-resistant...
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Sputum microbiome may augur treatment success in NTM-PD
- Author:
- Neil Osterweil
Patients cured of nontuberculosis mycobacterial infections with antibiotics had greater species diversity in sputum than those with refractory...
News
ICIs improve pCR rates in early ER+/HER2– breast cancer
- Author:
- Neil Osterweil
Nivolumab and pembrolizumab boosted pathologic complete response rates when added to neoadjuvant and adjuvant therapy in patients with high-risk...
News
No benefit to adding ICI to chemo in triple-negative breast cancer: study
- Author:
- Neil Osterweil
There were no differences in 5-year event-free survival among patients with TNBC who received neoadjuvant chemotherapy with or without...
News
Adjuvant abemaciclib-ET combo shows long-term benefit in high-risk early breast cancer
- Author:
- Neil Osterweil
Invasive disease–free and distant recurrence–free survival were better with the CDK4/6 inhibitor plus endocrine therapy than endocrine therapy...
News
Asthma severity higher among LGBTQ+ population
- Author:
- Neil Osterweil
SGM respondents were significantly more likely to have had asthma attacks requiring steroid use in the past years.
News
Pulmonary hypertension increases ARDS mortality risk
- Author:
- Neil Osterweil
The presence of PH was associated with about a 50% higher risk for in-hospital mortality.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lynch_David_PA2023_web.jpg)
The dawning age of therapy for Friedreich ataxia
- Author:
- Neil Osterweil
The first therapy to target the underlying pathology of Friedreich ataxia was approved in 2023. Other drug and genetic therapies are in the...
News
Nintedanib dose reductions in IPF may do no harm
- Author:
- Neil Osterweil
Patients with idiopathic pulmonary fibrosis who required dose reductions had similar all-cause mortality and death rates vs. patients on the full...
News
Dietary changes to microbiome may improve lung function
- Author:
- Neil Osterweil
What we eat and what’s in the gut may influence lung health for better or worse.